Electromed, Inc. (NYSEMKT:ELMD) Director William Eckles bought 20,000 shares of the company’s stock in a transaction dated Thursday, November 10th. The shares were purchased at an average cost of $3.61 per share, with a total value of $72,200.00. Following the acquisition, the director now directly owns 13,072 shares of the company’s stock, valued at approximately $47,189.92. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Electromed, Inc. (NYSEMKT:ELMD) opened at 3.93 on Thursday. Electromed, Inc. has a 12 month low of $1.55 and a 12 month high of $6.26. The company has a market cap of $32.29 million, a PE ratio of 14.56 and a beta of 0.89. The company has a 50 day moving average price of $4.28 and a 200-day moving average price of $4.37.

Electromed (NYSEMKT:ELMD) last announced its quarterly earnings data on Tuesday, November 8th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by $0.01. The business earned $5.50 million during the quarter, compared to analysts’ expectations of $5.90 million. Equities analysts predict that Electromed, Inc. will post $0.13 earnings per share for the current fiscal year.

A number of brokerages recently commented on ELMD. Zacks Investment Research upgraded Electromed from a “sell” rating to a “hold” rating in a research report on Tuesday, November 8th. TheStreet upgraded Electromed from a “hold” rating to a “buy” rating in a research report on Friday, September 16th.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alambic Investment Management L.P. boosted its stake in shares of Electromed by 28.0% in the second quarter. Alambic Investment Management L.P. now owns 29,571 shares of the company’s stock worth $114,000 after buying an additional 6,474 shares during the period. Eagle Global Advisors LLC bought a new stake in shares of Electromed during the second quarter worth about $134,000. Creative Planning boosted its stake in shares of Electromed by 3.0% in the third quarter. Creative Planning now owns 34,000 shares of the company’s stock worth $156,000 after buying an additional 1,000 shares during the period. Acrospire Investment Management LLC boosted its stake in shares of Electromed by 32.4% in the second quarter. Acrospire Investment Management LLC now owns 43,009 shares of the company’s stock worth $166,000 after buying an additional 10,527 shares during the period. Finally, Barclays PLC boosted its stake in shares of Electromed by 66.4% in the second quarter. Barclays PLC now owns 48,600 shares of the company’s stock worth $187,000 after buying an additional 19,400 shares during the period.

Electromed Company Profile

Electromed, Inc develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company’s products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others.

Receive News & Stock Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related stocks with our FREE daily email newsletter.